Judit Müller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Judit Müller has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Gyorgy Tibor Balogh
Department of Pharmaceutical Chemistry, Semmelweis University, Hőgyes Endre Str. 9, H-1092 Budapest, Hungary
7 shared publications Árpád Könczöl
Compound Profiling Laboratory, Gedeon Richter Plc., Gyömrői u. 19-21., H-1475 Budapest, Hungary
5 shared publications- Eszter Riethmüller
Department of Pharmacognosy, Semmelweis University, 1085 Budapest, Hungary
2 shared publications Attila Balogh
Budapest University of Technology and Economics, Department of Organic Chemistry and Technology, Hungary
1 shared publicationAttila Halász
Gedeon Richter Plc., Department of Discovery Pharmacokinetics, Hungary
1 shared publicationAttila Marosi
Semmelweis University, Department of Pharmaceutical Chemistry, Hungary
1 shared publication
Latest Publications
- 1 November 2015
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 79, 53-60
Tuning the predictive capacity of the PAMPA-BBB model
- 1 November 2015
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 79, 53-60
Tuning the predictive capacity of the PAMPA-BBB model
- 1 August 2015
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 491 (1-2) , 180-189
In vitro dissolution–permeation evaluation of an electrospun cyclodextrin-based formulation of aripiprazole using μFlux™
- 1 August 2015
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 491 (1-2) , 180-189
In vitro dissolution–permeation evaluation of an electrospun cyclodextrin-based formulation of aripiprazole using μFlux™
- 1 July 2015
- Published by Elsevier in Tetrahedron: Asymmetry
- Vol. 26 (12-13) , 650-656
Synthesis and enantioselective transport studies of optically active lipophilic proton-ionizable crown ethers containing a diarylphosphinic acid unit
- 1 July 2015
- Published by Elsevier in Tetrahedron: Asymmetry
- Vol. 26 (12-13) , 650-656
Synthesis and enantioselective transport studies of optically active lipophilic proton-ionizable crown ethers containing a diarylphosphinic acid unit
- 1 February 2015
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 104, 47-48
A model lacking relevant literature comparison
- 1 February 2015
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 104, 47-48
A model lacking relevant literature comparison
- 8 April 2013
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 76 (4) , 655-663
Applicability of a Blood–Brain Barrier Specific Artificial Membrane Permeability Assay at the Early Stage of Natural Product-Based CNS Drug Discovery
While numerous natural products (NPs) possess activity on central nervous system (CNS) targets, there has been no analytical approach to effectively identify compounds with high brain penetration potential in complex mixtures at the early stage of drug discovery. To overcome this issue, the performance of an in vitro parallel artificial membrane permeability assay for the blood–brain barrier (PAMPA-BBB) for natural products and for plant extracts has been validated and characterized. It was found that the PAMPA-BBB assay preserves its predictive power in the case of natural products and provides high phytochemical selectivity, which enables its use as a unique filtering tool in terms of selecting brain-penetrable compounds from plant extracts. Moreover, the present study has demonstrated that simple modifications in the assay design allow the direct use of PAMPA-BBB filtered samples in a dereplication process, as performed by NMR and LC-MS. The applicability of this procedure was demonstrated using extracts prepared from Tanacetum parthenium, Vinca major, Salvia officinalis, and Corydalis cava, representing different types of chemical diversity and complexity. Thus, the proposed protocol represents a potentially valuable strategy in the NP-based CNS drug discovery environment with a high-throughput screening platform.
- 8 April 2013
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 76 (4) , 655-663
Applicability of a Blood–Brain Barrier Specific Artificial Membrane Permeability Assay at the Early Stage of Natural Product-Based CNS Drug Discovery
While numerous natural products (NPs) possess activity on central nervous system (CNS) targets, there has been no analytical approach to effectively identify compounds with high brain penetration potential in complex mixtures at the early stage of drug discovery. To overcome this issue, the performance of an in vitro parallel artificial membrane permeability assay for the blood–brain barrier (PAMPA-BBB) for natural products and for plant extracts has been validated and characterized. It was found that the PAMPA-BBB assay preserves its predictive power in the case of natural products and provides high phytochemical selectivity, which enables its use as a unique filtering tool in terms of selecting brain-penetrable compounds from plant extracts. Moreover, the present study has demonstrated that simple modifications in the assay design allow the direct use of PAMPA-BBB filtered samples in a dereplication process, as performed by NMR and LC-MS. The applicability of this procedure was demonstrated using extracts prepared from Tanacetum parthenium, Vinca major, Salvia officinalis, and Corydalis cava, representing different types of chemical diversity and complexity. Thus, the proposed protocol represents a potentially valuable strategy in the NP-based CNS drug discovery environment with a high-throughput screening platform.
- 1 April 2013
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 49 (1) , 81-89
pH-gradient PAMPA-based in vitro model assay for drug-induced phospholipidosis in early stage of drug discovery
- 1 April 2013
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 49 (1) , 81-89
pH-gradient PAMPA-based in vitro model assay for drug-induced phospholipidosis in early stage of drug discovery